ArticleCancer medicine2024

Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2- metastatic breast cancer: A single center real-world study in China.

Hanfang Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.